The common HRD-related gene mutations in PCa are BRCA2, ATM, and CHEK2, all of which are included in the molecular eligibility criteria of virtually all PARP inhibitor trials involving mCRPC patients [33]. Here, BRCA2 is linked to posterior cortical atrophy.